Camurus Reports the P-III (ACROINNOVA 2) Trial Data of Octreotide SC Depot (CAM2029) for Treating Acromegaly
Shots:
- The P-III (ACROINNOVA 2) trial assessed octreotide depot (SC, QM) in 135 (81 were new & 54 were roll-over from 24wk. ACROINNOVA 1 study) acromegaly patients, both controlled/uncontrolled on stable doses of SoC with 1st gen. somatostatin ligands at 52wks.
- Treatment increased the response rates by 12.7% (overall population) & 22.8% (new patients), with roll-over patients maintaining/regaining biochemical control, plus improved acromegaly symptom scores, patient satisfaction, QoL & self-injection evaluation score
- Safety was similar & well-tolerated without any new concerns; 1 patient had a moderate, treatment-related SAE that resolved & 1.5% discontinued due to AEs. Regulatory reviews are underway in the US (PDUFA: Oct 21, 2024) & EU
Ref: Camurus | Image: Camurus
Related News:- AstraZeneca Reports Updated Data from the P-III (ADJUVANT BR.31) Study of Imfinzi to Treat Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
